Rational Use of New and Emerging Agents for Hepatitis Delta Virus
Several emerging agents will soon be available for the treatment of hepatitis delta virus (HDV). Hear experts discuss rational use and combinations of new agents to treat patients with HDV.
Decera Clinical Education Infectious Disease Podcast · Cihan Yurdaydin MD, Heiner Wedemeyer MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:
- Assembly inhibitors (eg, lonafarnib)
- Entry inhibitors (eg, bulevirtide)
- Interferon lambda
- Nucleic acid polymers
- Small interfering RNA (siRNA) agents
Presenters:
Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany
Cihan Yurdadin, MD
Professor and Chief
Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey
Link to full program:
https://bit.ly/365VUlG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.